ProMIS Neurosciences, Inc. (PMN)
13.07
-0.90
(-6.48%)
USD |
NASDAQ |
Sep 03, 16:00
13.07
0.00 (0.00%)
After-Hours: 20:00
ProMIS Neurosciences Enterprise Value : 71.86M for Sept. 2, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 02, 2026 | 71.86M |
| September 01, 2026 | 66.26M |
| August 31, 2026 | 63.74M |
| August 28, 2026 | 70.16M |
| August 27, 2026 | 72.00M |
| August 26, 2026 | 76.21M |
| August 25, 2026 | 84.28M |
| August 24, 2026 | 79.26M |
| August 21, 2026 | 76.66M |
| August 20, 2026 | 80.25M |
| August 19, 2026 | 78.00M |
| August 18, 2026 | 80.87M |
| August 17, 2026 | 78.00M |
| August 14, 2026 | 79.80M |
| August 13, 2026 | 79.17M |
| August 12, 2026 | 76.57M |
| August 11, 2026 | 80.78M |
| August 10, 2026 | 78.54M |
| August 07, 2026 | 78.45M |
| August 06, 2026 | 66.08M |
| August 05, 2026 | 67.42M |
| August 04, 2026 | 68.23M |
| August 03, 2026 | 73.34M |
| July 31, 2026 | 69.57M |
| July 30, 2026 | 80.34M |
| Date | Value |
|---|---|
| July 29, 2026 | 72.62M |
| July 28, 2026 | 76.75M |
| July 27, 2026 | 51.64M |
| July 24, 2026 | 55.94M |
| July 23, 2026 | 59.62M |
| July 22, 2026 | 72.00M |
| July 21, 2026 | 76.48M |
| July 20, 2026 | 81.73M |
| July 17, 2026 | 82.76M |
| July 16, 2026 | 65.81M |
| July 15, 2026 | 72.13M |
| July 14, 2026 | 69.04M |
| July 13, 2026 | 61.32M |
| July 10, 2026 | 74.33M |
| July 09, 2026 | 74.51M |
| July 08, 2026 | 70.11M |
| July 07, 2026 | 68.05M |
| July 06, 2026 | 69.48M |
| July 02, 2026 | 66.26M |
| July 01, 2026 | 67.15M |
| June 30, 2026 | 64.55M |
| June 29, 2026 | 32.55M |
| June 26, 2026 | 30.58M |
| June 25, 2026 | 28.07M |
| June 24, 2026 | 27.98M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Edesa Biotech, Inc. | 43.93M |
| Arrowhead Pharmaceuticals, Inc. | 11.82B |
| Oncolytics Biotech, Inc. | 106.01M |
| Sangamo Therapeutics, Inc. | 62.59M |
| Sarepta Therapeutics, Inc. | 2.709B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.73M |
| Total Expenses (Quarterly) | 11.73M |
| EPS Diluted (Quarterly) | -1.283 |
| Earnings Yield | -102.8% |
| Normalized Earnings Yield | -102.79 |